Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Patients With Advanced Solid Tumors

NCT01253837 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT01253837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01253837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Patients With Advanced Solid Tumors
Lead sponsor
Philogen S.p.A.
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2007
Completion date
September 30, 2011
Enrollment
34 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, solid tumors